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Abstract 
Pain is the most common symptom in rheumatic diseases. However, the severity of pain 
does not correlate with pathology. The lack of an objective test for pain results in clinicians 
consider pain in patients with fibromyalgia as psychological. Research over the last two 
decade using functional neuroimaging especially functional MRI scan have demonstrated 
objectively that patients with fibromyalgia were not malingering. Pain processing is complex 
and multiple regions of the brain are involved. One consistent finding is decrease activity in 
regions of the brain involved in pain inhibitory pathways suggesting this is one of the 
fundamental pathophysiology processes in fibromyalgia.   
 
Introduction 
Pain is a common and dominant symptom in rheumatic diseases1. Patients with rheumatoid 
arthritis (RA) rank pain as the most important and disabling symptom, with a major impact 
on quality of life2,3. In many patients, the severity of pain does not correlate with disease 
activity or underlying pathology4,5. In RA, pain may be present in patients in clinical 
remission. In osteoarthritis (OA), many people with severe radiographic abnormalities 
report no joint pain and joint replacement does not always alleviate pain6.  A disconnect 
between symptoms of pain and anatomical abnormalities is particularly evident in the 
patients with fibromyalgia, in whom local tender points are seen in the absence of local 
pathology. The absence of an objective test for pain leads many clinicians to consider pain in 
such cases as psychological and patients are malingering7.  
 
The advent of the functional neuroimaging has allowed researchers to study processing of 
pain in the brain objectively over the last two decades in fibromyalgia and other rheumatic 
diseases. Results from these studies have indicated that processing of pain is complex, 
involving different regions of the brain. Pain is more than a “sensation”. This review will 
discuss principles of functional neuroimaging and key findings in rheumatic diseases, 
particularly in fibromyalgia. 
   
Functional neuroimaging 
Several methods are available to assess cerebral function, including electroencephalography 
(EEG), functional Magnetic Resonance Imaging (fMRI) by blood oxygenation level dependent 
(BOLD) or arterial spin labelling (ASL), and radio-isotope imaging by Single-photon emission 
computed tomography (SPECT) or positron emission tomography (PET). 
 
Neuroimaging of Pain 
The strength of neuroimaging of pain lays mainly in its objectivity. Initially, studies have 
focussed on acute evoked pain in healthy volunteers with experimental stimuli to analyze 
effects of analgesic medications8. These studies indicated that many regions in the brain are 
involved in the processing of pain, which has led to the concept of a ‘pain matrix’. These 
regions include the anterior cingulate cortex, primary somatosensory cortex, secondary 
somatosensory cortex, prefrontal cortex, insular cortex, hypothalamus, thalamus, amygdala 
and brainstem. The notion that there is a unique and fixed cerebral signature for pain 
perception has proven to be too simplistic. Recent studies have shown that the response to 
pain is affected by the type of painful stimulus, chronicity of symptoms, disease condition, 
and imaging method9,10. Indeed, similar brain networks can be activated by the anticipation 
of pain11, and may be involved in processing the saliency of sensory events12. Current 
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thought is that the network of brain areas which are associated with pain processing is 
dynamic9,10. In patients with chronic pain conditions, more involvement is seen of affective-
cognitive regions such as the insula cortex than the sensory discriminatory region 
(somatosensory cortex), highlighting differences between chronic pain and acute pain8. This 
has influenced study design and development of new technology in neuroimaging. 
 
Electroencepalography (EEG) Studies 
EEG records the electrical neuronal activity. It can be used to monitor the activity of 
different brain region over time. When combined with painful stimuli, EEG has been used to 
study cerebral response to pain which has been used in rheumatic diseases13. However, it 
can only be used to study only superficial brain regions, and has not proven of substantial 
value to understand chronic pain. 
 
Functional Neuroimaging using Radio-isotopes 
SPECT and PET use radio-isotope tracers to assess regional cerebral blood flow. Using 
specific tracer, PET can also assess cerebral metabolism.  
 
Single Photon Emission Computed Tomography (SPECT) 
SPECT was the first functional neuroimaging tool used for research in patients with 
fibromyalgia. A small study in 10 patients found lower activity in the thalamus and caudate 
nucleus when compared to 7 controls14. A subsequent SPECT study with a larger sample of 
fibromyalgia patients and healthy controls found decreased regional cerebral blood flow in 
the thalamus and pontine tegmentum15. Reduced regional cerebral blood flow in the 
thalamus and caudate nucleus were replicated in a third SPECT study of FM patients16. 
However, SPECT images are of low resolution are prone to artefact, and therefore has been 
replaced by PET and fMRI. 
 
Positron Emission Tomography (PET) 
Unlike SPECT which uses gamma rays emitting radio-isotopes, PET uses radio-isotopes which 
emit positrons. The latter leads to higher sensitivity and resolution. In fibromyalgia, a small 
study of 8 patients using PET reported higher regional cerebral blood flow in the 
retrosplenial cortex but reduced regional cerebral blood flow in the frontal, temporal, 
parietal, and occipital cortices17. Using 18F-fluorodeoxyglucose as a tracer, PET can assess 
glucose metabolism so can assess metabolic activity as well as regional cerebral blood flow. 
However, Yunus et al. using a PET with 18F-fluorodeoxyglucose tracer found no difference in 
resting state between the patient and control groups18.  Harris et al used 11C-carfentanil to 
evaluate μ-opioid receptor binding in patients with fibromyalgia. The binding potential of 
μ-opioid receptors was reduced in several areas of the brain in patients with fibromyalgia 
compared with healthy individuals, including the rostral anterior cingular cortex, nucleus 
accumbens and amygdala, which are correlated significantly with pain and depression19. 
Endogenous opioids and opioid receptors are important for pain inhibition. The results from 
this study suggest pain modulation is impaired in patients with fibromyalgia and may explain 
the limited efficacy of opioids in fibromyalgia20. 
 
fMRI Studies 
Blood Oxygenation Level Dependent (BOLD) fMRI of Evoked Pain 
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Increased neuronal activity leads to increased local blood flow and conversion of 
oxygenated haemoglobin to deoxyhaemoglobin. Oxyhaemoglobin and deoxyhaemoglobin 
have different magnetic characteristics. fMRI scan can detect these changes to provide a 
measure of neuronal activity.  
 
BOLD fMRI studies are based on comparing activities of different brain regions in response 
to painful and non-painful stimuli. The BOLD fMRI studies have been used extensively in 
experimental studies of acute pain using various experimental pain stimuli from electric to 
pressure induced pain8. It has also been used in many rheumatic diseases including 
RA21,13,22, OA5 and fibromyalgia. In OA, BOLD fMRI, has identified regions of the brain 
involved in processing evoked pain and spontaneous pain23. In RA, activation of brain region 
correlated with tender-swollen joint ratio and depression, suggesting depression is related 
to pain processing21. 
 
In fibromyalgia, Gracely et al first demonstrated objectively using BOLD fMRI that cerebral 
activities matched with patient-reported pain24. At the time, many clinicians regard 
fibromyalgia as a ‘‘functional/psychological disorder” since the severity of pain does not 
correspond with pathology. Using a device which applied a varying degree of pressure on 
the thumbnail ranging from non-painful to painful. Cerebral activity in patients with 
fibromyalgia was compared to healthy control subjects. Importantly, painful and non-painful 
stimuli were applied randomly during BOLD fMRI so that subjects could not anticipate 
whether the stimuli should be painful or non-painful. BOLD fMRI imaging documented that 
activities in the brain are similar in patients with fibromyalgia and control subjects, but 
occurred at lower pressure-pain stimuli in fibromyalgia patients. For the first time, it 
provided objective evidence that patients with fibromyalgia are not malingering, but rather 
they are more sensitive to pain provocation than normal individuals.  
 
A subsequent study using the same method found that patients with fibromyalgia had 
reduced activity in the rostral anterior cingulate cortex when compared to controls25. This 
region of the brain has been linked to the descending pain inhibitory pathways. The 
attenuated response to pain in this brain region is the first demonstration of a specific brain 
region in which the impairment of pain inhibition is seen. This observation was supported by 
a study using PET imaging assessing μ-opioid receptor binding discussed earlier in this 
review19. Further analysis from this study found that the rostral anterior cingulate cortex 
displayed significantly reduced connectivity to the amygdala, hippocampus, and brainstem 
in patients with fibromyalgia compared with healthy controls26.  
 
Reduced connectivity of the pain inhibitory network suggested that the dysfunction of the 
descending pain modulatory network plays an important role in the pathophysiology of 
fibromyalgia. These findings were further supported by structural MRI analyses in patients 
with fibromyalgia, indicating decreased cortical thickness, decreased brain volumes, and 
decreased functional regional coherence in the rostral anterior cingulate cortex27. The 
morphometric changes were more pronounced with longer exposure to FM pain.  
 
fMRI has also been used to assess cerebral pain processing in response to anti-depressant. A 
double-blind, placebo-controlled clinical trial was conducted with milnacipran, a serotonin-
norepinephrine reuptake inhibitor.  fMRI scans were performed before and after treatment 
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in 92 patients with fibromyalgia28. Following treatment, responders to milnacipran exhibited 
significantly higher activity in the posterior cingulate cortex compared with responders to 
placebo as well as non-responders to milnacipran. Changes in activity in the posterior 
cingulate cortex were correlated significantly with reduction in patient-reported pain. This 
observation suggested that milnacipran improved pain in fibromyalgia by increasing the 
activity of the posterior cingulate cortex, which is a part of the brain regions implicated in 
pain inhibition.  
 
Despite being objective, one of the weaknesses of BOLD fMRI imaging is its reliance on 
“experimental” pain stimuli. In fibromyalgia, in which “allodynia” or “tenderness” is a 
classical feature, assessing evoked pain and pressure pain threshold is logical. However, in 
many rheumatic diseases, including fibromyalgia, patients report "spontaneous” pain in the 
absence of noxious stimuli. The relevance of observations made through BOLD fMRI imaging 
to "spontaneous” pain reported by patients has been questioned29. One way of addressing 
this possible weakness is to utilise resting state BOLD fMRI or arterial spin labelling. 
 
Resting state BOLD fMRI 
Resting state BOLD fMRI monitors changes in brain activity over time without painful 
stimuli. It was used to identify the default mode network (DMN), a network of brain 
regions that is active ‘at rest’. DMN is thought to be involved in self-referential orientation 
and monitoring. In many chronic pain conditions, spontaneous pain was associated with 
aberrant connectivity in the DMN30,31. In fibromyalgia, decreased connectivity DMN has 
been localized to the pain inhibitory network26,32 supported the findings from evoked pain 
study25. 
 
Arterial Spin Labeling (ASL) 
ASL measures regional cerebral blood flow by magnetically labelling water. ASL is suitable 
for studying spontaneous pain33, both acute34 and chronic including recently in thumb OA35, 
in which patient-reported pain was associated with increased activity in the somatosensory 
cortex, insular cortex, cingulate cortex, thalamus, amygdala, and hippocampus. In 
fibromyalgia, regional cerebral blood flow in the basal ganglion is correlated significantly 
with physical disability36. regional cerebral blood flow in the right putamen and right lateral 
globus pallidus was? reduced in patients compared with control subjects.  
 
Summary 
Functional neuroimaging has provided an objective assessment of pain processing in the 
brain. A network of brain regions is involved. In fibromyalgia, different neuroimaging tools 
have demonstrated dysfunction in the connectivity of DMN suggesting the key 
pathophysiological feature in fibromyalgia is a dysfunctional inhibitory pain network.  
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